Ginkgo Bioworks Announces Participation in Jefferies Virtual Synthetic Biology Week
Ginkgo Bioworks (NYSE: DNA) has announced its participation in the Jefferies Virtual Synthetic Biology Week, scheduled for March 22, 2022, at 10:00 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) has announced its participation in the Jefferies Virtual Synthetic Biology Week, scheduled for March 22, 2022, at 10:00 a.m. Eastern Time. Management will engage in a fireside chat during this event. Details, including a webcast link and a replay, will be available on the company's investor relations website. Ginkgo operates a platform for cell programming, supporting various biotechnology applications across markets like food, agriculture, and pharmaceuticals, while also contributing to COVID-19 response efforts.
Positive
- Participation in Jefferies Virtual Synthetic Biology Week demonstrates Ginkgo's engagement in the synthetic biology sector.
- Platform enables diverse biotechnology applications across multiple markets, suggesting versatile revenue potential.
Negative
- None.
Details
News Market Reaction – DNA
The recorded move for DNA in the trading session of this news was +2.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 15, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in a fireside chat at Jefferies Virtual Synthetic Biology Week, on March 22, 2022, at 10:00 a.m. Eastern Time.
Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visit https://www.ginkgobioworks.com/.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-jefferies-virtual-synthetic-biology-week-301502443.html
SOURCE Ginkgo Bioworks
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.